Sanofi India declares 8% growth in net sales for Q4-2024
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Offers affordable, high-quality solutions for diabetes care
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Prithwish has close to 28 years of experience in a Commercial role
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
Subscribe To Our Newsletter & Stay Updated